8-K: HeartBeam Secures $17 Million At-the-Market Offering, Terminates Prior Agreement

HeartBeam, Inc. has entered into a sales agreement with Public Ventures, LLC for a potential $17 million at-the-market offering of its common stock, while terminating a previous agreement with A.G.P./Alliance Global Partners.

Summary

• HeartBeam, Inc. has entered into a sales agreement with Public Ventures, LLC, allowing the company to offer and sell up to $17 million of its common stock.
• The shares will be sold through an at-the-market offering, as defined by SEC rules.
• Public Ventures will receive a 3.0% commission on the gross proceeds from each sale.
• HeartBeam intends to use the net proceeds for working capital and general corporate purposes.
• To facilitate this new agreement, HeartBeam terminated its previous sales agreement with A.G.P./Alliance Global Partners.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While it secures potential funding, it also highlights the costs and risks associated with the offering. The termination of the previous agreement adds a note of caution.

Positives

• The new sales agreement provides HeartBeam with access to up to $17 million in capital.
• The at-the-market offering structure allows for flexible and potentially less dilutive capital raising.
• The company has secured a new sales agent, Public Ventures, LLC, to manage the offering.

Negatives

• The company will incur a 3.0% commission on the gross proceeds from each sale, reducing the net capital raised.
• There is no guarantee that the company will sell all or any of the shares under the agreement.
• The company terminated a previous sales agreement, which may indicate a change in strategy or dissatisfaction with the prior arrangement.

Risks

• The company may not be able to sell all of the shares under the agreement, limiting the amount of capital raised.
• The at-the-market offering could potentially dilute existing shareholders.
• The company's reliance on the capital raise for working capital may indicate financial pressures.
• The termination of the previous sales agreement could lead to uncertainty or additional costs.

Future Outlook

HeartBeam intends to use the net proceeds from the offering for working capital and other general corporate purposes, and any other purposes that may be stated in any future prospectus supplement. The company cannot provide any assurances that it will issue any shares pursuant to the sales agreement.

Management Comments

• The company currently intends to use any net proceeds from the Offering for working capital and other general corporate purposes, and any other purposes that may be stated in any future prospectus supplement.

Industry Context

At-the-market offerings are a common method for publicly traded companies to raise capital, providing flexibility and potentially reducing dilution compared to traditional offerings. The termination of the previous agreement and entry into a new one suggests a strategic shift in the company's approach to capital raising.

Comparison to Industry Standards

• At-the-market offerings are a common practice for companies of HeartBeam's size and stage, particularly in the biotech and medical device sectors.
• A 3% commission is within the typical range for such offerings, although it can vary based on the size and complexity of the deal.
• Comparable companies that have used ATM offerings include Xometry Inc. (XMTR) and Amylyx Pharmaceuticals, Inc. (AMLX).
• The success of the offering will depend on market conditions and investor appetite for HeartBeam's stock.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company's ability to fund operations and growth will be improved by the capital raise.
• Employees may benefit from the company's improved financial position.
• Creditors may view the capital raise positively as it strengthens the company's balance sheet.

Next Steps

• HeartBeam will begin offering shares through Public Ventures, LLC.
• The company will file necessary prospectus supplements with the SEC.
• The company will use the net proceeds for working capital and general corporate purposes.

Key Dates

Keywords

at-the-market offering, capital raise, common stock, sales agreement, Public Ventures, HeartBeam, working capital, securities, commission, AGP